Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 17/20 | 0.47 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.42 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | TERT | O14746 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1028127 | 0.92 | BRD4 (0.44) | BRD4CHRNB2CHRNA4CYP3A4TSHR | |
| SCHEMBL17307557 | 0.85 | BRD4 (0.41) | BRD4CHRNB2CHRNA4 | |
| SCHEMBL6988890 | 0.83 | BRD4 (0.53) | BRD4CHRNB2CHRNA4 | |
| SCHEMBL17307553 | 0.81 | BRD4 (0.41) | BRD4CHRNB2CHRNA4 | |
| SCHEMBL29133012 | 0.81 | CHRNB2 (0.41) | BRD4CHRNB2CHRNA4 | |
| SCHEMBL30619654 | 0.81 | CHRNB2 (0.41) | BRD4CHRNB2CHRNA4 | |
| SCHEMBL6850450 | 0.81 | CHRNB2 (0.41) | BRD4CHRNB2CHRNA4 | |
| SCHEMBL30622064 | 0.78 | BRD4 (0.46) | BRD4CHRNB2CHRNA4CYP3A4 | |
| SCHEMBL30690136 | 0.78 | BRD4 (0.43) | BRD4CHRNB2CHRNA4 | |
| SCHEMBL26688298 | 0.78 | BRD4 (0.46) | BRD4CHRNB2CHRNA4CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105085427-B | Benzo [ d ] isoxazole compound and application thereof | 中国科学院广州生物医药与健康研究院 | 2018-06-05 | — | — | CN | disclosed |
| CN-105085427-A | Benzo [ d ] isoxazole compound and application thereof | GUANGZHOU INST BIOMED & HEALTH | 2015-11-25 | — | — | CN | disclosed |
| US-8513235-B2 | Homocysteine synthase inhibitor | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2013-08-20 | — | — | US | disclosed |
| EP-2486925-A1 | THERAPEUTIC AGENT FOR CEREBRAL INFARCTION | Mitsubishi Tanabe Pharma Corporation (JP) | 2012-08-15 | — | — | EP | disclosed |
| US-20120196824-A1 | THERAPEUTIC AGENT FOR CEREBRAL INFARCTION | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-08-02 | — | — | US | disclosed |
| US-20110034440-A1 | HOMOCYSTEINE SYNTHASE INHIBITOR | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-02-10 | — | — | US | disclosed |
| EP-2275404-A1 | HOMOCYSTEINE SYNTHASE INHIBITOR | Mitsubishi Tanabe Pharma Corporation (JP) | 2011-01-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120196824-A1 | THERAPEUTIC AGENT FOR CEREBRAL INFARCTION | FABP7, TIMP3, MMP11 | BRD4 1310/4885CHRNB2 3440/4885CHRNA4 3468/4885 |
| US-20110034440-A1 | HOMOCYSTEINE SYNTHASE INHIBITOR | BHMT, CBS, BHMT2 | BRD4 2156/4885CHRNB2 4441/4885CHRNA4 4468/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.